Skip to main content

Advertisement

Advertisement

Singapore

21 new COVID-19 cases in Singapore, all imported

21 new COVID-19 cases in Singapore, all imported

People in protective face masks walk at Changi Airport Terminal 3. (Photo: Calvin Oh)

SINGAPORE: There were 21 new COVID-19 cases in Singapore as of noon on Thursday (Apr 8), said the Ministry of Health (MOH). 

All the new infections were imported and were placed on stay-home notice upon arrival in Singapore.

Five Singaporeans and a permanent resident who returned from India and the United States were among the new cases reported on Thursday. 

Three are student's pass holders who arrived from India and another two are work pass holders who travelled from India and the Maldives. 

Another nine cases are work permit holders who came from Bangladesh, India, Indonesia and Ukraine. Three of these cases are foreign domestic workers. 

The remaining case is a short-term visit pass holder who arrived from the Philippines for a work project in Singapore.

Twenty-four more cases have been discharged from hospitals or community isolation facilities, taking the total recoveries to 60,284.

There are 43 cases who are still in hospital. Most are stable or improving, and one is in critical condition in the intensive care unit.




​​​​​​​A total of 218 cases are isolated and cared for at community facilities. 

Overall, the number of new cases in the community has decreased from three in the week before to two in the past week, said MOH, adding that the number of unlinked cases in the community has also decreased from three in the week before to two in the past week. 

CANCER DRUG MAY BE ABLE TO TREAT INFLAMMATION CAUSED BY COVID-19

A widely available and inexpensive drug used for cancer treatment could potentially be used in the treatment of COVID-19, according to a study by Singapore and US researchers. 

They found that the chemotherapeutic drug, called Topotecan, reduced the severity and death rates of infection by the virus that causes COVID-19, by suppressing inflammation in the lungs of laboratory animals.

The safety and efficacy of the treatment in humans will soon be evaluated at clinical sites around the world, said the National University Cancer Institute, Singapore, adding that its team has secured a research grant to conduct a Phase 1 clinical trial of Topotecan in COVID-19 patients.

READ: Cancer drug may be able to treat inflammation caused by COVID-19 virus: Singapore-US study

As of Thursday, Singapore has reported 60,575 COVID-19 cases and 30 fatalities.

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram

Source: CNA/vc

Advertisement

Also worth reading

Advertisement